NCT03448042 2026-02-27A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing CancersGenentech, Inc.Phase 1 Active not recruiting123 enrolled
NCT02320435 2026-02-12A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical TrialHoffmann-La RochePhase 3 Active not recruiting154 enrolled
NCT03916094 2022-05-05Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2Shanghai Henlius BiotechPhase 1 Completed11 enrolled